The effects of anesthetics on tumor progression

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 5, Issue 1, 2013, Pages 1-10

  Mao, Lifang ^a   Lin, Suizhen ^b   Lin, Jun ^a  

^a SUNY Downstate Medical Center   (United States)

^b Guangzhou Cellproteck Pharmaceutical CO Ltd   (China)

Author keywords

Local anesthetics; Metastasis; Opioids; Recurrence; Regional anesthesia; Volatile anesthetics; Voltage gated sodium channels

Indexed keywords

17 METHYLNALTREXONE; ANESTHETIC AGENT; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHALATION ANESTHETIC AGENT; INTERLEUKIN 12; INTERLEUKIN 2; KETAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MATRIX METALLOPROTEINASE; MORPHINE; OPIATE; OPIATE ANTAGONIST; PHENYTOIN; PROPOFOL; TETRACAINE; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VOLTAGE GATED SODIUM CHANNEL;

ABDOMINAL CANCER; ANGIOGENESIS; BREAST CANCER; CANCER INVASION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOLOGY; EPIDURAL ANESTHESIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL ANESTHESIA; REVIEW; TUMOR GROWTH;

EID: 84875023052     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Eschwege P, Dumas F, Blanchet P, Le Maire V, Benoit G, Jardin A, Lacour B and Loric S. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995; 346: 1528-1530.
2. Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, Herfarth C and von Knebel Doeberitz M. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 1998; 4: 343-348.
3. Yamashita J, Matsuo A, Kurusu Y, Saishoji T, Hayashi N and Ogawa M. Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study. J Thorac Cardiovasc Surg 2002; 124: 299-305.
4. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M and Mori M. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011; 29: 1547-1555.
5. Peach G, Kim C, Zacharakis E, Purkayastha S and Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 2010; 102: 1327-1334.
6. Gottschalk A, Sharma S, Ford J, Durieux ME and Tiouririne M. Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth Analg 2010; 110: 1636-1643.
7. Snyder GL and Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105: 106-115.
8. Tavare AN, Perry NJ, Benzonana LL, Takata M and Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer 2012; 130: 1237-1250.
9. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E and Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105: 660-664.
10. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI and Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008; 109: 180-187.
11. Christopherson R, James KE, Tableman M, Marshall P and Johnson FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 2008; 107: 325-332.
12. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR and Sessler DI. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 2011; 342: d1491.
13. Day A, Smith R, Jourdan I, Fawcett W, Scott M and Rockall T. Retrospective analysis of the effect of postoperative analgesia on survival in patients after laparoscopic resection of colorectal cancer. Br J Anaesth 2012; 109: 185-190.
14. Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME and Nemergut EC. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 2010; 113: 27-34.
15. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA and Sauter PK. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993; 217: 447-455; discussion 456-447.
16. Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, Mantilla CB and Warner DO. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. Jama 2004; 291: 1092-1099.
17. Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Catala E, Bryce DA, Cousins M and Pool GE. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005; 16: 825-833.
18. Kurosawa S. Anesthesia in patients with cancer disorders. Curr Opin Anaesthesiol 2012; 25: 376-384.
19. Kehlet H. Manipulation of the metabolic response in clinical practice. World J Surg 2000; 24: 690-695.
20. Yokoyama M, Itano Y, Mizobuchi S, Nakatsuka H, Kaku R, Takashima T and Hirakawa M. The effects of epidural block on the distribution of lymphocyte subsets and natural-killer cell activity in patients with and without pain. Anesth Analg 2001; 92: 463-469.
21. Wada H, Seki S, Takahashi T, Kawarabayashi N, Higuchi H, Habu Y, Sugahara S and Kazama T. Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/ TH2 cytokine balance. Anesthesiology 2007; 106: 499-506.
22. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K and Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg 2003; 97: 1331-1339.
23. Kelbel I and Weiss M. Anaesthetics and immune function. Curr Opin Anaesthesiol 2001; 14: 685-691.
24. Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. Channels (Austin) 2012; 6: 5.
25. Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, Brackenbury WJ, Theodorou D, Koyuturk M, Kaya H, Battaloglu E, De Bella MT, Slade MJ, Tolhurst R, Palmieri C, Jiang J, Latchman DS, Coombes RC and Djamgoz MB. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 2005; 11: 5381-5389.
26. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, Sarvazyan N, Irby R, Strausberg RL, Hales TG, Stuart JM and Lee NH. Voltagegated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res 2010; 70: 6957-6967.
27. Lucchinetti E, Awad AE, Rahman M, Feng J, Lou PH, Zhang L, Ionescu L, Lemieux H, Thebaud B and Zaugg M. Antiproliferative effects of local anesthetics on mesenchymal stem cells: potential implications for tumor spreading and wound healing. Anesthesiology 2012; 116: 841-856.
28. Yoon JR, Whipple RA, Balzer EM, Cho EH, Matrone MA, Peckham M and Martin SS. Local anesthetics inhibit kinesin motility and microtentacle protrusions in human epithelial and breast tumor cells. Breast Cancer Res Treat 2011; 129: 691-701.
29. Piegeler T, Votta-Velis EG, Liu G, Place AT, Schwartz DE, Beck-Schimmer B, Minshall RD and Borgeat A. Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade. Anesthesiology 2012; 117: 548-559.
30. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D and Hebbel RP. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62: 4491-4498.
31. Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA and Gupta K. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 2011; 113: 1353-1364.
32. Ecimovic P, Murray D, Doran P, McDonald J, Lambert DG and Buggy DJ. Direct effect of morphine on breast cancer cell function in vitro: role of the NET1 gene. Br J Anaesth 2011; 107: 916-923.
33. Hieber S, Huhn R, Hollmann MW, Weber NC and Preckel B. Hypoxia-inducible factor 1 and related gene products in anaesthetic-induced preconditioning. Eur J Anaesthesiol 2009; 26: 201-206.
34. Kawaraguchi Y, Horikawa YT, Murphy AN, Murray F, Miyanohara A, Ali SS, Head BP, Patel PM, Roth DM and Patel HH. Volatile anesthetics protect cancer cells against tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via caveolins. Anesthesiology 2011; 115: 499-508.
35. Wu GJ, Chen WF, Sung CS, Jean YH, Hung CH, Chen FA, Hsieh MH and Wen ZH. Isoflurane attenuates dynorphin-induced cytotoxicity and downregulation of Bcl-2 expression in differentiated neuroblastoma SH-SY5Y cells. Acta Anaesthesiol Scand 2009; 53: 55-60.
36. Miao Y, Zhang Y, Wan H, Chen L and Wang F. GABA-receptor agonist, propofol inhibits invasion of colon carcinoma cells. Biomed Pharmacother 2010; 64: 583-588.
37. Mammoto T, Mukai M, Mammoto A, Yamanaka Y, Hayashi Y, Mashimo T, Kishi Y and Nakamura H. Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett 2002; 184: 165-170.
38. Li M and Xiong ZG. Ion channels as targets for cancer therapy. Int J Physiol Pathophysiol Pharmacol 2011; 3: 156-166.
39. Onkal R and Djamgoz MB. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer. Eur J Pharmacol 2009; 625: 206-219.
40. Xu YQ, Pickoff AS and Clarkson CW. Evidence for developmental changes in sodium channel inactivation gating and sodium channel block by phenytoin in rat cardiac myocytes. Circ Res 1991; 69: 644-656.
41. Xu YQ, Pickoff AS and Clarkson CW. Developmental changes in the effects of lidocaine on sodium channels in rat cardiac myocytes. J Pharmacol Exp Ther 1992; 262: 670-676.
42. Brackenbury WJ and Djamgoz MB. Activity-dependent regulation of voltage-gated Na+ channel expression in Mat-LyLu rat prostate cancer cell line. J Physiol 2006; 573: 343-356.
43. Chioni AM, Brackenbury WJ, Calhoun JD, Isom LL and Djamgoz MB. A novel adhesion molecule in human breast cancer cells: voltagegated Na+ channel beta1 subunit. Int J Biochem Cell Biol 2009; 41: 1216-1227.
44. Roger S, Rollin J, Barascu A, Besson P, Raynal PI, Iochmann S, Lei M, Bougnoux P, Gruel Y and Le Guennec JY. Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines. Int J Biochem Cell Biol 2007; 39: 774-786.
45. Yildirim S, Altun S, Gumushan H, Patel A and Djamgoz MB. Voltage-gated sodium channel activity promotes prostate cancer metastasis in vivo. Cancer Lett 2012; 323: 58-61.
46. Yang M, Kozminski DJ, Wold LA, Modak R, Calhoun JD, Isom LL and Brackenbury WJ. Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res Treat 2012; 134: 603-615.
47. Abdul M and Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res 2001; 21: 2045-2048.
48. Onganer PU and Djamgoz MB. Small-cell lung cancer (human): potentiation of endocytic membrane activity by voltage-gated Na(+) channel expression in vitro. J Membr Biol 2005; 204: 67-75.
49. Andrikopoulos P, Fraser SP, Patterson L, Ahmad Z, Burcu H, Ottaviani D, Diss JK, Box C, Eccles SA and Djamgoz MB. Angiogenic functions of voltage-gated Na+ Channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling. J Biol Chem 2011; 286: 16846-16860.
50. Fedder C, Beck-Schimmer B, Aguirre J, Hasler M, Roth-Z'graggen B, Urner M, Kalberer S, Schlicker A, Votta-Velis G, Bonvini JM, Graetz K and Borgeat A. In vitro exposure of human fibroblasts to local anaesthetics impairs cell growth. Clin Exp Immunol 2010; 162: 280-288.
51. Mammoto T, Higashiyama S, Mukai M, Mammoto A, Ayaki M, Mashimo T, Hayashi Y, Kishi Y, Nakamura H and Akedo H. Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF). J Cell Physiol 2002; 192: 351-358.
52. Fraser SP, Salvador V, Manning EA, Mizal J, Altun S, Raza M, Berridge RJ and Djamgoz MB. Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. J Cell Physiol 2003; 195: 479-487.
53. Trapaidze N, Gomes I, Cvejic S, Bansinath M and Devi LA. Opioid receptor endocytosis and activation of MAP kinase pathway. Brain Res Mol Brain Res 2000; 76: 220-228.
54. Singleton PA, Lingen MW, Fekete MJ, Garcia JG and Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 2006; 72: 3-11.
55. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J and Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112: 558-567.
56. Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y and Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett 2002; 187: 121-127.
57. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H and McLean SA. mu-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 2012; 116: 896-902.
58. Lennon FE, Moss J and Singleton PA. The muopioid receptor in cancer progression: is there a direct effect? Anesthesiology 2012; 116: 940-945.
59. Kitano H, Kirsch JR, Hurn PD and Murphy SJ. Inhalational anesthetics as neuroprotectants or chemical preconditioning agents in ischemic brain. J Cereb Blood Flow Metab 2007; 27: 1108-1128.
60. Li QF, Zhu YS and Jiang H. Isoflurane preconditioning activates HIF-1alpha, iNOS and Erk1/2 and protects against oxygen-glucose deprivation neuronal injury. Brain Res 2008; 1245: 26-35.
61. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
62. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P and Charpin C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005; 116: 734-739.
63. Muller-Edenborn B, Roth-Z'graggen B, Bartnicka K, Borgeat A, Hoos A, Borsig L and BeckSchimmer B. Volatile anesthetics reduce invasion of colorectal cancer cells through down-regulation of matrix metalloproteinase-9. Anesthesiology 2012; 117: 293-301.
64. Liang H, Gu M, Yang C, Wang H, Wen X and Zhou Q. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth 2012; 26: 381-392.
65. Shapiro J, Jersky J, Katzav S, Feldman M and Segal S. Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors. J Clin Invest 1981; 68: 678-685.
66. Fleischmann E, Marschalek C, Schlemitz K, Dalton JE, Gruenberger T, Herbst F, Kurz A and Sessler DI. Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial. BMC Anesthesiol 2009; 9: 1.
67. Kushida A, Inada T and Shingu K. Enhancement of antitumor immunity after propofol treatment in mice. Immunopharmacol Immunotoxicol 2007; 29: 477-486.
68. Harlow BL and Cramer DW. Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States). Cancer Causes Control 1995; 6: 130-134.
69. Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC and Devereux TR. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis 2003; 24: 757-770.
70. Halapy E, Kreiger N, Cotterchio M and Sloan M. Benzodiazepines and risk for breast cancer. Ann Epidemiol 2006; 16: 632-636.
71. Pottegard A, Friis S, Andersen M and Hallas J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol 2012; 2012: 12001.
72. Kurata J. [Anesthetic mechanisms revealed by functional brain imaging]. Masui 2011; 60: 566-573.
73. Kurosawa S and Kato M. Anesthetics, immune cells, and immune responses. J Anesth 2008; 22: 263-277.
74. Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W and Wallin BA. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 728-734; discussion 734-725.
75. Brown JM and Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-447.